- mab: Bamlanivimab
  num_ref: 20
  num_fold: 146
  avail: EUA
  class: RBM Class II
  pdb: 7KMG
  institute: Eli Lilly
- mab: Etesevimab
  num_ref: 23
  num_fold: 283
  avail: EUA
  class: RBM Class I
  pdb: 7C01
  institute: Eli Lilly
- mab: Casirivimab
  num_ref: 33
  num_fold: 347
  avail: EUA
  class: RBM Class I
  pdb: 6XDG
  institute: Regeneron
- mab: Imdevimab
  num_ref: 33
  num_fold: 346
  avail: EUA
  class: RBD Core Cluster I
  pdb: 6XDG
  institute: Regeneron
- mab: Sotrovimab
  num_ref: 16
  num_fold: 207
  avail: EUA
  class: RBD Core Cluster I
  pdb: 6WPS
  institute: Vir Biotechnol / GlaxoSmithKline
- mab: Cilgavimab
  num_ref: 11
  num_fold: 52
  avail: Completed phase III
  class: RBM Class II
  pdb: 7L7E
  institute: AstraZeneca / Vanderbilt
- mab: Tixagevimab
  num_ref: 10
  num_fold: 48
  avail: Completed phase III
  class: RBM Class I
  pdb: 7L7E
  institute: AstraZeneca / Vanderbilt
- mab: BRII-196
  num_ref: 5
  num_fold: 157
  avail: Completed phase III
  class: RBM Class I
  pdb: 7CDI
  institute: BRII Biosciences
- mab: BRII-198
  num_ref: 3
  num_fold: 58
  avail: Completed phase III
  class: RBD Core Cluster II
  pdb: ''
  institute: BRII Biosciences
- mab: Regdanvimab
  num_ref: 4
  num_fold: 20
  avail: Phase III
  class: RBM Class I
  pdb: 7CM4
  institute: Celltrion
- mab: C135
  num_ref: 4
  num_fold: 105
  avail: Phase III
  class: RBD Core Cluster I
  pdb: 7K8Z
  institute: Rockefeller University / Roche
- mab: C144
  num_ref: 4
  num_fold: 138
  avail: Phase III
  class: RBM Class III
  pdb: 7K90
  institute: Rockefeller University / Roche
